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How Can We Support the Use of Oral PrEP Among Young
Women who Sell Sex? A PrEP Cascade Analysis
B. Hensen, PhD,a F. Machingura, PhD,b J. Busza, MSc,c I. Birdthistle, PhD,d S.T. Chabata, MSc,b
T. Chiyaka, MSc,b S. Floyd, MSc,d G. Jamali, MSc,b P. Mushati, MSc,b J. Hargreaves, PhD,c and
F.M. Cowan, MBBSb,e
Background: We constructed self-reported pre-exposure prophy-
laxis (PrEP) cascades and explored factors associated with and
barriers to PrEP use to inform efforts to support PrEP use among
young women who sell sex.
Methods: Using self-reported data from HIV-negative young
women who sell sex enrolled into a cohort study using
respondent-driven sampling in Zimbabwe, we constructed PrEP
cascades assessing knowledge of, ever offered, ever used, and
current PrEP use in 2017 and 2019. We used logistic regression to
examine factors associated with PrEP use by 2019. Through
qualitative interviews with 43 women enrolled in the cohort, we
investigated barriers to PrEP use.
Results: At enrollment, 50% of women had heard of PrEP, 12%
had ever been offered PrEP, and 7% ever used PrEP. Over time, all
cascade domains: 96% of women had heard of and 55% reported an
active offer of PrEP. Among women retained in the study in 2019
(56%; n = 538), 34% ever took PrEP by 2019. PrEP use was
associated with, at enrollment, reporting more clients in the past
month (10+: 45% vs 1–3: 27% adjOR = 1.71 95% CI: 1.06 to 2.76),
duration of selling sex (24% ,2 years vs 38% 2–3 years;
adjOR = 0.51 95% CI: 0.32 to 0.83), and having visited a female
sex worker program in the past 12 months (55% vs 27%;
adjOR = 2.92 95% CI: 1.91 to 4.46). Qualitative interviews revealed
fear of disclosing sex work, HIV-related/ART-related stigma, and
(opportunity) costs of accessing PrEP as barriers to use.
Conclusion: PrEP use was associated with factors known to
increase HIV risk. Fear of stigma, disclosure, and supply-side
barriers need to be addressed to increase women’s ability to
use PrEP.
Key Words: HIV infections, HIV prevention, oral pre-exposure
prophylaxis, women, female sex workers, Zimbabwe
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INTRODUCTION
Adolescent girls and young women aged 15–24 years
account for ,26% of new HIV infections in eastern and
southern Africa.1 Among this population, young women who
sell sex (YWSS) are at particularly high risk of HIV, reporting
higher numbers of partners and less condom use than their
peers not involved in sex work and having poorer access to
health services than older female sex workers (FSWs).2–4
Reducing HIV incidence among YWSS requires combination
prevention that is responsive to their needs and addresses
barriers to their service use.5
Oral pre-exposure prophylaxis (PrEP) is efficacious
when taken as prescribed.6,7 As YWSS often struggle to
negotiate condom use, PrEP offers women more choice and
control over their sexual health.8 For PrEP to be effective at
population levels, individuals must have high demand; PrEP
services need to be available, accessible, and acceptable; and
those who initiate PrEP must adhere during periods of use. To
maximize the potential impact of PrEP, cascades and
continuums have been used to identify gaps in delivery and
use,9 target programs to support initiation, and optimize
adherence and continued use.10
In Zimbabwe, YWSS were among the target population
for the DREAMS initiative, which sought to reduce HIV
incidence by 40% among adolescent girls and young women
in 10 African countries.11,12 In districts where DREAMS
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funding was available, PrEP availability was a key service for
YWSS combined with efforts to increase demand and support
use. We previously showed that although it is plausible that
DREAMS may have contributed to reduced HIV risk among
YWSS, it did not achieve 40% reduction in HIV incidence.13
We also showed that new HIV infections did not differ by
ever-reporting PrEP use in 2019. To inform efforts to support
PrEP use among YWSS, we constructed a PrEP cascade to
investigate and understand reasons for gaps in PrEP use and
explored whether factors likely to influence demand for and
opportunities to access PrEP were associated with uptake.
METHODS
Study Location and Population
Data were collected from YWSS aged 18–24 years
residing in two Zimbabwean cities selected for the DREAMS
initiative. In each city, the national FSW HIV prevention
program, “Sisters with a Voice” (Sisters), offered HIV testing,
condom promotion and distribution, community mobilization,
and referral to legal advice through static clinics. At Sisters,
YWSS were offered referrals to other DREAMS partners
offering additional HIV prevention services, including oral
PrEP and social protection.14
Data Collection
Respondent-driven sampling (RDS) was used to recruit
YWSS to the DREAMS impact evaluation.15 Described
elsewhere, the evaluation estimated the impact of DREAMS
on HIV incidence among women recruited through RDS and
followed up 24-month post-enrollment. Before RDS, YWSS
identified through mapping and representative of the typology
of sex work in each city were invited to act as “seeds”.15,16 To
initiate RDS, these “seed” participants were given two
vouchers to recruit YWSS, whom they knew and knew sold
sex. Eligible participants were given two vouchers to recruit
two further women. This process continued over six recruit-
ment waves.15 YWSS aged 18–24 years who sold sex were
eligible, defined as sex in exchange for material goods/money
where the sex would not happen in the absence of
the exchange.
Behavioral Survey
Consenting women completed an interviewer-
administered questionnaire and were offered HIV-testing
services.15 All women received the result of their HIV test.
Women were followed up 12- and 24-months postenrollment
(2018 and 2019, respectively), asked to complete the same
questionnaire, and offered HIV testing as at enrollment. The
questionnaire elicited women’s demographics, history of
selling sex, sexual behaviors, access to HIV prevention
services, and engagement with the broader package of
services available through DREAMS.
Qualitative Interviews
Between September 2017 and November 2019, 43
DREAMS participants from among the women recruited
through RDS were purposively selected for interview.
Women were selected for diversity in age and levels of
participation across the range of DREAMS services. Inter-
views were conducted 12 and 24-months post-enrollment and
explored motivations for engaging with DREAMS services
and any challenges encountered during participation in
DREAMS. A shorter version of the interview topic guide
was piloted before RDS. We interviewed 19 YWSS selected
as “seeds” for the RDS and explored feasibility of asking
about their sexual relationships, involvement in selling sex,
engagement with care, barriers to accessing HIV prevention
and treatment, and interest in activities to be offered under
DREAMS. Interview guides were subsequently expanded to
elicit perceptions and experiences and explore if and how
involvement in DREAMS affected their health, behavior, and
well-being. Sixteen respondents were interviewed .1 time to
understand changing experiences and perceptions. Two
female social scientists conducted interviews, which lasted
30–60 minutes and were audio recorded, in Shona
or Ndebele.
Outcomes and Explanatory Variables
The cascade used in this analysis was informed by the
framework proposed by Schaefer et al,10 which conceptual-
izes that demand for, access to, and use of/adherence to an
HIV prevention product are influenced by individual-level
and structural-level factors. Self-reported outcomes of interest
for the PrEP cascade included ever having heard of, ever
being offered, ever using PrEP, and current PrEP use. For
women followed up in 2018 and/or 2019, women were
defined as having heard of, ever being offered, or ever using
PrEP by 2019 if they reported these outcomes at any point
during the study. A further outcome of interest was
HIV seroconversion.
To understand gaps across the PrEP cascade, we
described domains (measured in 2019) believed to influence
each step. For having heard of PrEP, measures included
knowledge of other prevention measures (sex with one HIV-
negative partner, consistent condom use, and medical male
circumcision). For this step, we also explored perceptions of
other YWSS9 willingness to take PrEP and whether PrEP was
believed to make it easy for YWSS to protect themselves
from HIV. Measures for potential reasons for gaps in ever
being offered PrEP included: attending a Sisters clinic and
testing for HIV in the past 6 months. Measures explored as
underlying gaps in ever and current use of PrEP included:
perceived support for PrEP use from friends/peers, family and
sexual partners, condomless sex with regular partners and
clients in the past month, and self-perceived risk of HIV in the
next 12 months.
Explanatory variables explored for their association
with PrEP use included those likely to influence decisions and
opportunities to initiate PrEP.17,18 These variables, measured
at enrollment, included age, marital status, educational
attainment, being at risk of common mental health disorders,
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measured using the Shona Symptom Questionnaire,19
whether women self-identified as a FSW, age at which
women started and duration of selling sex, client numbers
in the past month, self-perceived HIV risk in the next 12
months, knowledge of other HIV prevention measures,
perceived support for PrEP use, and attendance at a Sisters
clinic in the 12 months before enrollment. In addition, we
explored whether ever being offered PrEP by 2019 and
women’s identification as an FSW between 2017 and 2019
were associated with PrEP use.
Data Analysis
We restricted analyses to women testing HIV-negative at
enrollment. First, we described enrollment characteristics and
behaviors of all women and of those retained in the 2019 follow-
up survey. Among these, we described the number and pro-
portion of new HIV infections by PrEP use and explored whether
steps in the cascade were associated with seroconversion.
Second, using data from all the three surveys, we
constructed PrEP cascades for 2017 and 2019. Using the
framework proposed by Schaefer et al,10 we estimated levels
of having heard of, ever offered, ever using, and current use
of PrEP at enrollment (2017) and by 2019. For each step, we
described potential reasons for gaps, as described, and,
adjusting for age and site, explored whether these factors
differed within each step. To further understand gaps in the
cascade, we conducted thematic content analysis of qualita-
tive interviews with the specific aim of interrogating each
stage of the prevention cascade as perceived and experienced
by women participating in DREAMS. This involved recoding
transcripts into broad codes relevant to each step of the
cascade. Data were transcribed and translated into English
and imported into NVivo-12. Thematic analysis was achieved
by rereading transcripts to identify emerging themes and
reconciliation of codes after iterative discussions. We present
data on women’s understanding of PrEP, where they accessed
services, and narratives around choosing to initiate PrEP and
subsequent (dis)continuation.
In our third step, we used logistic regression to explore
the association between the explanatory variables described
and PrEP use by 2019. Our crude models adjusted for age at
enrollment and included a fixed effect for site. All variables
were explored in adjusted analyses, in which we adjusted for
variables associated with PrEP use at P , 0.10 level in crude
analyses. Adjustment followed the distal–proximal frame-
work used in an analysis of enrollment data,2 and as such, we
did not adjust for variables considered proximal to the out-
come relative to the variable of interest. As our analysis used
data at follow-up and half the women were not retained, we
did not RDS weight the data. This aligns with our analysis of
the primary outcome.13
Ethics
The Medical Research Council Zimbabwe (MRCZ/A/
2085) and the London School of Hygiene & Tropical
Medicine (11835) approved the study. Written informed
consent was obtained from all women before participation.
RESULTS
Enrollment Characteristics and Retention
Among 963 HIV-negative women enrolled in the study,
20.5% (n = 197) were aged 18 years and .50% considered
themselves FSWs (66.5%, n = 633) and reported $3 clients
in the past month (57.2%, n = 551). Most considered their risk
of HIV in the next 12 months to be low/small (62.8%,
n = 501). Half had knowledge of other HIV prevention
measures (48.3%; n = 465). More than half the women were
retained in the study in 2018 (54.4%; n = 524) and 2019
(55.9%; n = 538). Retention in 2019 was higher among
women who, at enrollment, reported selling sex for $4 years
and started selling sex at the age of 10–14 years (Table 1).
By 2019, 5.8% (n = 31) of women seroconverted,
among whom 38.7% (n = 12) reported ever using PrEP
between 2017 and 2019. Adjusting for age and site, there was
little evidence for an association between steps in the cascade
and HIV seroconversion (Suppl Table 1, http://links.lww.
com/QAI/B675).
Cascade Step 1: Ever Heard of PrEP
Over time, all domains of the cascade increased (Fig.
1). By 2019, most women had heard of PrEP (95.7%;
n = 514) compared with half (50.3%; n = 481) in 2017.
Never having heard of PrEP was higher among women who
disagreed (22.7%; n = 5/22) that PrEP would make it easier
for women to protect themselves from HIV than among
women agreeing with the statement (5.1% n =16/316; Table
2). In qualitative interviews (Table 3), women described how
they heard of and informed their friends about PrEP:
I know about it, when you go to Sisters [Clinic]
they always talk about it [PrEP] and it feels like a
song (chuckles). I was supposed to go collect it
[PrEP] on Wednesday but I did not go.. I did
not have bus fare (22 years) BYOLN03R3.
Cascade Step 2: Ever Offered PrEP
In 2017, few women had been offered PrEP (11.7%,
n = 112); by 2019, 54.9% (n = 294) reported ever being
offered PrEP. Never being actively offered PrEP was lower
among women who had been to a Sisters clinic (40.1% vs
never: 64.0%) and had tested for HIV in the past six months
(41.8% vs not tested 56.5%) (Table 2). The cost and
opportunity cost of accessing PrEP, including missing school,
limited women’s ability to go to clinics where PrEP was
available:
I was referred for PrEP in town but time does not
permit...I do [want to take PrEP] but time won’t
allow me.Please bring some for me if you can.
Because I really want it. (22 years) BYOCS25R1
Some women had been to the clinic but then were asked
to come back the following day:
The first time I wanted to go and get PrEP I did not
have the time to go there because of school. When I had the
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TABLE 1. Characteristics and Behaviors of Women Testing HIV-Negative at Enrollment (N = 963) and Retention of These Women












Overall 963 538 100% 55.9%
Age at enrollment (yr)
18 197 (20.5) 109 20.3% 55.3% 0.69
19 164 (17.0) 99 18.4% 60.4%
20 112 (11.6) 56 10.4% 50.0%
21 133 (13.8) 75 13.9% 56.4%
22 149 (15.5) 80 14.9% 53.7%
23 155 (16.1) 91 16.9% 58.7%
24 53 (5.5) 28 5.2% 52.8%
Marital status at enrollment
Single/never married 668 (69.4) 361 67.1% 54.0% 0.31
Married/cohabiting 21 (2.2) 12 2.2% 57.1%
Divorced 270 (28.0) 164 30.5% 60.7%
Widowed 4 (0.4) 1 0.2% 25.0%
Highest level of education attained
No education/incomplete primary 28 (2.9) 15 2.8% 53.6% 0.70
Complete primary education 61 (6.3) 32 6.0% 52.5%
Form 1–3 393 (40.8) 216 40.2% 55.0%
Form 4–6 471 (48.9) 271 50.4% 57.5%
College, cert, or degree 10 (1.0) 4 0.7% 40.0%
Whether food insecure past mo
No 418 (43.4) 229 42.6% 54.8% 0.71
Yes 545 (56.6) 309 57.4% 56.7%
Experienced common mental health illness
No 595 (61.8) 331 61.5% 55.6% 0.86
Yes 368 (38.2) 207 38.5% 56.3%
Self-identifies as an FSW
No 319 (33.5) 167 31.4% 52.4% 0.15
Yes 633 (66.4) 365 68.6% 57.7%
Age started selling sex
10–14 36 (3.7) 26 4.8% 72.2% 0.02
15–17 424 (44.1) 250 46.6% 59.0%
18–19 297 (30.9) 150 27.9% 50.5%
20–24 205 (21.3) 111 20.7% 54.2%
Duration of selling sex
,2 270 (28.1) 136 25.3% 50.4% 0.05
2–3 420 (43.7) 236 43.9% 56.2%
4+ 272 (28.3) 165 30.7% 60.7%
No of partners sold sex to in the past mo
1–3 412 (42.8) 219 40.7% 53.2% 0.31
4–9 295 (30.6) 173 32.2% 58.6%
10+ 256 (26.6) 146 27.1% 57.0%
Perceived HIV risk†
No chance: no possibility of becoming infected 194 (22.8) 94 19.8% 48.5% 0.04
Small chance: could happen but not likely 307 (36.1) 178 37.5% 58.0%
Moderate chance: some possibility of becoming
infected
121 (14.2) 71 15.0% 58.7%
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time and wanted PrEP, I was told to come the following day
and never went back again. (23 years) MTRCS30R2.
Cascade Step 3: Ever Taken PrEP
In 2017, 6.9% (n = 66) of women reported ever taking
PrEP, increasing to 33.6% (n = 181) by 2019. There was little
difference in PrEP use by perceived support for PrEP use and
condomless sex in the past month (Table 2). PrEP use was
strongly associated with ever being offered PrEP (60.5% vs
1.2%). In risk factor analyses (Table 4), ever using PrEP by
2019 was higher among women who, at enrollment, reported
10+ clients in the past month (44.5% vs 26.5% for 1–3
clients; adjOR = 1.71 95% CI: 1.06 to 2.76) and had been to a
Sisters clinic in the past 12 months (54.5% vs 26.7%,
adjOR = 2.92 95% CI: 1.91 to 4.46), with weaker evidence
that use was higher among women who were ever/currently
married (42.9% vs 29.1%, adjOR = 1.51 95% CI: 0.98
to 2.32).
PrEP use was lower among women who, at enroll-
ment, reported selling sex for ,2 years (24.3% vs 2–3-
years: 37.7%, adjOR = 0.51 95% CI: 0.32 to 0.83) and who
disagreed that friend/peers would support their PrEP use
(24.2% vs 36.9%; adjOR = 0.54 95% CI: 0.31 to 0.95).
Half the women self-identified as FSWs throughout the
study (48.1%, n = 255). There was borderline evidence that
PrEP use was associated with self-identification: use was
lowest among women who never identified as an FSW
(26.7%, n = 28/105) and who identified as an FSW at
enrollment but not at follow-up (25.0%, n = 27/109). In
qualitative interviews, women revealed a willingness to
take PrEP but had concerns that it would disclose their
sex work.
Ok, I did not want it because if I get it [PrEP] and take it
home, my family would like to know why I have PrEP and
TABLE 1. (Continued ) Characteristics and Behaviors of Women Testing HIV-Negative at Enrollment (N = 963) and Retention of












High chance: likely to become infected 175 (20.6) 96 20.2% 54.9%
I do not know 53 (6.2) 36 7.6% 67.9%
Knowledge of prevention measures‡
No 498 (51.7) 278 51.7% 55.8% 0.97
Yes 465 (48.3) 260 48.3% 55.9%
*Wald test, adjusted for site.
†113 missing data or do not know response.
‡Knowledge that having sex with one HIV-negative partner, consistent condom use, and male circumcision are measures that can reduce the risk of HIV infection for individuals.
FIGURE 1. Self-reported PrEP use cascades
among young women who sell sex in Zimbabwe,
2017–2019.
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Number of Women by Gaps in the Cascade
(n, Row %)
Potential Reasons Underlying Gaps in Demand for PrEP by 2019
Had Not Heard of PrEP (n = 23) P*
Knowledge of other HIV prevention measures in 2019
No 211 (39.3) 12 (5.7) 0.18
Yes 326 (60.7) 11 (3.4)
Perceived risk of HIV in the next 12 months (N = 483)
None/small 397 (82.0) 17 (4.3) 0.39
Medium/high risk 87 (18.0) 6 (6.9)
Most young women like me would be willing to take
PrEP
Strongly agree 123 (23.0) 2 (1.6) 0.34
Agree 283 (53.0) 14 (5.0)
Disagree 100 (18.7) 7 (7.0)
Strongly disagree 28 (5.3) 0
PrEP would make it easier for women like me to protect
ourselves
Strongly agree 193 (36.1) 2 (1.0) 0.004
Agree 316 (59.2) 16 (5.1)
Disagree 22 (4.1) 5 (22.7)
Strongly disagree 3 (0.6) 0
Potential Reasons Underlying Gaps in Ever Being Offered PrEP by 2019 (N = 536)
Never Offered PrEP (n = 242)
Ever been to a Sisters clinic
No 114 (21.3) 73 (64.0) ,0.001
Yes 422 (78.7) 169 (40.1)
Tested for HIV in the past 6 mo
No 124 (23.1) 70 (56.5) 0.001
Yes 412 (76.9) 172 (41.8)
Potential Reasons Underlying Gaps in Ever Used PrEP by 2019
All Women
Never Used PrEP
(n = 357; Row %
of all Women) P*
Not Using PrEP Currently
(n = 474; Row %
of all Women) P*
Any condomless sex with regular partners in the past mo
No 275 (51.3) 184 (66.9) 0.59 240 (87.3) 0.48
Yes 261 (48.7) 171 (65.5) 234 (89.7)
Any condomless sex with clients in the past mo
No 475 (88.8) 317 (66.7) 0.38 424 (89.3) 0.09
Yes 60 (11.2) 38 (63.3) 50 (83.3)
Perceived risk of HIV in the next 12 months (N = 484)
None/small 397 (82.0) 265 (66.8) 0.77 345 (86.9) 0.28
Medium/high risk 87 (18.0) 57 (65.5) 79 (90.8)
I would receive support to take PrEP from: friends/peers
Strongly agree 114 (21.4) 65 (18.3) 0.38 94 (82.5) 0.32
Agree 297 (55.6) 203 (57.2) 264 (88.9)
Disagree 87 (16.3) 61 (17.2) 80 (92.0)
Strongly disagree 36 (6.8) 26 (7.3) 34 (94.4)
I would receive support to take PrEP from: sexual
partners
Strongly agree 70 (13.1) 39 (11.0) 0.22 56 (80.0) 0.24
Agree 228 (42.7) 149 (42.0) 201 (88.2)
Disagree 157 (29.4) 112 (31.6) 143 (91.1)
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what it is for, exposing my business [sex work] (22
years) BYOLN06R1.
Initiating PrEP was hindered by broader structural
factors such as stigma, lack of support for PrEP use, alongside
financial and opportunity costs of traveling to the clinic, and
related to how PrEP was offered and needs to be taken:
.I wanted to take PrEP but the processes are too
tedious and long for me, I fear that I may also
forget to take the tablets [PrEP]. Another thing that
got me worried is that when I told him [boyfriend]
that PrEP protects me from HIV he asked me
where the HIV would be coming from and he
asked why I wanted to take it alone and exclude
him. So I got scared. (20 years) BYOCS33R2
Cascade Step 4: Currently Taking PrEP
In 2019, current PrEP use remained low at 11.5%
(n = 62). Among women not currently using PrEP, a higher
percentage (strongly) disagreed that they would receive
support for PrEP use from family (Table 2). Reasons for
discontinuing PrEP use were varied (Table 3) and included
side effects and, as with PrEP use, reflected broader
structural factors:
When my brother found the pills [PrEP] he got
very cross, he yelled and beat me up. He asked
me why I had not disclosed my [HIV] status to
him. This was because he was not educated on
PrEP [assumed she was HIV-positive]. My
grandmother, however, knew that I was taking
PrEP. She was fine with it. The way my brother
was shouting attracted everyone’s attention and
the neighbors heard all his insults about him
saying I am sick. That made me suicidal and I
also decided to stop taking it. (24
years) BYOLN02R2.
Discontinuation of PrEP was also driven by perceived
low HIV risk behaviors and recognizing the need to adhere
to taking PrEP daily, leading some women to
prefer condoms:
I thought it is better to use condoms instead of the
pills because I feared that I could not adhere to
them. (18 years) BYOCS26R1.
One woman described many reasons for discontinuing
PrEP and later tested HIV-positive:
When I tested HIV-negative, they told me about
the PrEP. So I got my PrEP for three months and
then I stopped. I stopped taking the pills for many
reasons. First, it was cumbersome and burdensome
to take the pills every day and when I was not ill.
Secondly, I felt more hungry than before, and lastly
my brother was suspecting that I was on ART for
HIV . so I was increasingly embarrassed about
taking them [PrEP] ... after stopping I tested HIV-
positive . (19 years) MTRCS20R1.
DISCUSSION
After introduction of PrEP in the two DREAMS sites,
just over half the women in our study reported ever being
offered PrEP by 2019 and one-third ever used PrEP. Use
was higher among women reporting an active offer of PrEP
and was associated with factors likely to influence HIV risk,
including being married/cohabiting, number of years selling
sex, and reporting higher number of clients. Our mixed
method analysis revealed that lack of support for use, costs
and opportunity cost to travel to the clinic, side effects, and
daily pill taking as reasons for observed gaps in the
PrEP cascade.
Our study is subject to limitations. Data on an offer of
PrEP use and current PrEP use were self-reported and
therefore subject to error.20 Almost half the women recruited
were lost to follow-up. Our outcomes are subject to bias if
PrEP knowledge and use differ by follow-up. Our risk factor
analysis may be subject to bias if PrEP use is differentially
misreported by the variables explored. However, as our
Table 2. (Continued ) Potential Reasons Underlying Gaps in the Cascade Among Women Retained in, and as Reported in, the 2019
Survey (N = 538)
Potential Reasons Underlying Gaps in Ever Used PrEP by 2019
All Women
Never Used PrEP
(n = 357; Row %
of all Women) P*
Not Using PrEP Currently
(n = 474; Row %
of all Women) P*
Strongly disagree 79 (14.8) 55 (15.5) 72 (91.1)
I would receive support to take PrEP from: family
Strongly agree 100 (18.7) 57 (16.1) 0.24 82 (82.0) 0.10
Agree 249 (46.6) 166 (46.8) 217 (87.2)
Disagree 109 (20.4) 74 (20.9) 100 (91.7)
Strongly disagree 76 (14.3) 58 (16.3) 73 (96.1)
*P value from the Wald test, adjusted for age and the two study sites.
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TABLE 3. Understanding Reasons Underlying Gaps in the PrEP Cascade Through Qualitative Interviews (N = 43)
Cascade Step
Women’s knowledge of PrEP and where they
can access these services
They [Sister’s clinic] advised me to use protection [condoms] and they told me about PrEP and
its use...They told me to use it to prevent HIV infection and that I can get it at the New Start
Center . I know of Umzingwane AIDS Council, CeSHHAR, Bekezela, and AVAC that
deal with PrEP. (22-year-old, site A) BYOLN05R1
They told me about it [PrEP]. I heard that they are pills that protect you from getting HIV even
if you have unprotected sex with an infected person. I even heard about it on the radio....
They offered it [PrEP] to us but I said I would come when ready. (21-year-old, site A)
BYOCS24R1
We were educated about PrEP in groups and I immediately wanted it. We were given referral
letters to start PrEP when we tested negative...It was near Blad Mission. (19-year-old, site
B) MTRLN04R1
I went to a place called [she forgot the name] . to have the pill [PrEP] that will prevent HIV
infection. I cannot get infected by HIV if I have sex with someone with HIV while using
PrEP every day (23-year-old, site B) MTRCS41R3
Yes, I accompanied a friend to FACT and the other to PSI they wanted pills, the PrEP pills.
(19-year-old, site B) MTRCS37R1
I then went with him to New Start Center since he wanted to be tested with his girlfriend, so I
asked them to explain about PrEP. (23-year-old, site B) MTRCS22R1
The only place where they offered me PrEP was at Sisters where they encouraged me to take it
but I did not. (22-year-old, site A) BYOLN03R2
Barriers to being offered PrEP They offered it to me, but something came up and I could not manage to go, I got really busy
(18-years-old, site B) MTRLN08R3
I want to take PrEP, but time would not allow me, I am too busy to go to the clinic for this. (22-
year-old, site A) BYOLN03R1
Reasons why women never started PrEP It is not because I did not want, but I realized that there was no need for me to use it [PrEP]
because I do not have unprotected sex. My boyfriend does not live in Zimbabwe, so I do not
have unprotected sex. (18-year-old, site A) BYOCS42R3
I did not like them .I do not like taking tablets. (20-year-old, site B) MTRLN14R1
She explained and asked me whether I wanted to be referred for PrEP and then I said no
because I was afraid that my mother would see the pills and she will ask me about those
pills. If she asks that then it will be hard for me to stay at home because she will know about
business [sex work] (19-year-old, site B) MTRLN09R1
I told them not to refer me. I will continue to use condoms. (19-year-old, site B)MTRLN09R1
The only place where they offered me PrEP was at Sisters [Sex Worker Clinic] where they
encouraged me to take it [PrEP]. But I did not [take PrEP] because the clinic is a bit far from
where I live and work. The problem was the time to commit to travel there because when
they wanted me to go to PSI, I was also needed at Kelvin where I work. (22-year-old, site A)
BYOLN03R2
What if my mother sees it [PrEP] I do not want her to see such things that is why I refused the
pills.(19-year-old, site B) MTRLN09R2
I do not like taking pills. So when I heard of pills I lost interest..to be honest I forgot if they
prevent [HIV] or not, because I did not have any interest in them. (20-year-old, site B)
MTRLN14R2
I do not really have problems taking them [pills], it is just that I initially did not understand the
way they are used. When I eventually did, I realized just do not want to take them because I
only use condoms to protect myself. (20-year-old, site A) BYOLN04R3
I do not think I will be able to take it [PrEP] every day (19-year-old, site B) MTRCS40R3
To be fair, I will not get sick if I do not take PrEP so I do not take it. Another reason is that at
home my mother does not know that this is what I do [sex work], so she might find them
and she will ask me what these pills are for and we might argue about it. Also, I fear that I
may forget to take them and end up contracting HIV. So, I decided not to take the pills as I
would rather use a condom... So I have actually started liking a condom. (18-year-old, site
B) MTRCS18R1
I am negative. I wanted to take PrEP but the processes are too tedious and long for me, I fear
that I may also forget to take the tablets [PrEP]. Another thing that got me worried is that
when I told him [boyfriend] that PrEP protects me from HIV he asked me where the HIV
would be coming from and he asked why I wanted to take it alone and exclude him. So I got
scared. (20-year-old, site A) BYOCS33R2
I use condoms a lot and they hardly break for me, so I have not really been actively considering
PrEP. (19-year-old, site B) MTRLN09R2
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explanatory variables were measured at enrollment and most
women had not yet used PrEP, we consider the risk of bias
low. Despite limitations, we recruited and followed up more
than 500 YWSS, who are underrepresented in research on
FSWs. Furthermore, we used data from two time points, with
our explanatory variables measured before most PrEP use.
Reported non-PrEP use was strongly associated with
not having been offered it. In Kenya, Were et al21 found that,
in the first two years of PrEP rollout (2017–2019), low
provider screening for PrEP eligibility was among the most
common missed opportunities for delivering PrEP to adoles-
cent girls and young women. In South Africa, a study among
FSWs and men who have sex with men found that 57% of
individuals who had never used PrEP had never been
proactively offered it.18 Fear of side effects was the primary
reason for declining use.18 Similar to findings from our
qualitative analysis, Emmanuel et al (2020)22 found that costs
and frequency of HIV testing were barriers to PrEP uptake
among FSWs in Nigeria. Using qualitative data collected
during the SEARCH trial in Kenya and Uganda, Camlin23
et al (2020) found that daily pill taking was considered a
bigger burden than HIV risk. Integrating PrEP into family
planning, sexual and reproductive health, and targeted
services is critical to increase opportunities to offer PrEP.24
With growing evidence of injectable PrEP efficacy,25 longer-
acting PrEP may remove some supply-side barriers and those
related to confusion between PrEP and ART.
In our study, a higher percentage of women offered
PrEP initiated it than in the SEARCH trial, where 27% of
high-risk individuals initiated PrEP.17 Our risk factor analysis
found no evidence that self-perceived HIV risk at enrollment
was associated with PrEP use. However, PrEP use was
highest among women who identified as a FSW throughout
the study and at follow-up, higher among women reporting
more clients and selling sex for longer. Similarly, our
qualitative findings underscore that women’s decision making
around PrEP includes consideration of risk based on sexual
behaviors, including condom use and their perception of
different sexual partners, with higher use among married/
cohabiting women. These findings are similar to those from a
qualitative study among serodiscordant couples in Zimbabwe,
which found that risk perception was linked to willingness to
take PrEP.26 These findings suggest that women in longer-
term, stable relationships—who may find condom negotiation
harder or condom use less pleasurable—–are seeking alter-
native prevention measures. Rather than focus on reduced
HIV risk and medicalize PrEP, efforts to increase demand
should focus on messaging around personal protection,
reduced sex-related anxiety, and increased sexual pleasure
with regular partners.27,28
TABLE 3. (Continued ) Understanding Reasons Underlying Gaps in the PrEP Cascade Through Qualitative Interviews (N = 43)
Cascade Step
I remember being told about it [PrEP], but I did not listen much about it..I did not have any
interest getting to know more about the service, to be honest..I thought it was one of those
useless programs. (23-year-old, site B) MTRCS22R1
Reasons why women stopped taking PrEP I used to skip taking them [PrEP] and then I eventually stopped because I was going to school
and feared that they would affect me, I often had headaches after taking them and I was
forced to sit down and rest making others suspicious at school. I am also not doing sex work
anymore because I have gotten back in school and I am now busy with my school. (18-year-
old, site B) MTRLN10R1
It is discouraging to repeatedly visit the clinic to get medication when you are not sick, so lost
interest on PrEP. Another thing is that I never have sex with anyone without protection
[condom], I felt like there is nothing it [PrEP] will help me with because I am using
protection (21-year-old, site B) MTRLN12R1
I did not like taking them [PrEP] ... They were too many and I decided to stop taking them.
They were giving me a tummy ache. (20-year-old, site B) MTRCS11R2
I thought it is better to use condoms instead of the pills because I feared that I could not adhere
to them. (18-year-old, site A) BYOCS26R1
I do not think I have had unprotected sex with any infected person, I use protection all the time.
I felt that it [PrEP] has no use for me (19-year-old, site B) MTRCS32R2
I stopped taking my medication [PrEP] last mo because I used to feel dizzy after taking them. I
would have headaches to such an extent that I could not see, then I would be forced to sit
down. It used to happen only for about five minutes but it was terrible. I also experienced a
rash it was also bad. (23-year-old, site B) MTRCS19R1
No particular reason. “Hapana” [nothing/no reason]. “Hapana” [I was neither motivated nor
persuaded] (20-year-old, site B) MTRLN16R2
No I have stopped now, I never went back there.Because I could not get transport money to
get back and also I did not have enough time because I was writing exams and my aunt also
did not have money for me to go to town. (19-year-old, site B) MTRLN16R1
They said I should keep coming to get refills, so I just did not pursue it. It was too burdensome.
(19-year-old, site B) MTRCS32R2
I started in June and stopped. I went there [clinic] and they said that I should come back in July
and I did not go back. I was in the rural areas; my father was ill. I then went back, and I was
given the pills and I am now taking them [PrEP] (22-year-old, site A) BYOCS43R3
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TABLE 4. Enrollment Characteristics and Behaviors of Young Women Testing HIV-Negative and Followed up in 2019 and the











Adjusted OR (95% CI)
Adjusted OR
(95% CI) P¶
Overall 538 100 181 33.6% —
Sociodemographics and history of selling sex at
enrollment
Age at time of survey (yr)
18 109 20.3 34 31.2% 1.03 (0.94 to 1.13) 1.03 (0.94 to 1.13) 0.53
19 99 18.4 34 34.3%
20 56 10.4 17 30.4%
21 75 13.9 20 26.7%
22 80 14.9 27 33.8%
23 91 16.9 38 41.8%
24 28 5.2 11 39.3%
Marital status
Single/never married 361 67.1 105 29.1% 1.00 1.00 0.06
Married/cohabiting/previously married 177 32.9 76 42.9% 1.51 (0.98 to 2.32) 1.51 (0.98 to 2.32)
Educational attainment*
No education/incomplete primary 15 2.8 8 53.3% 2.03 (0.71 to 5.86) 1.87 (0.65 to 5.42) 0.68
Complete primary education 32 6.0 12 37.5% 1.32 (0.61 to 2.85) 1.22 (0.56 to 266)
Form 1–3 216 40.2 76 35.2% 1.12 (0.76 to 1.64) 1.06 (0.72 to 1.57)
Form 4–6/college, cert, or degree 275 51.1 85 30.9% 1.00 1.00
At risk of common mental health disorders†
No 331 61.5 102 30.8% 1.00 1.00 0.24
Yes 207 38.5 79 38.2% 1.34 (0.92 to 1.94) 1.26 (0.86 to 1.83)
Whether YWSS considered herself an FSW†
(N = 532)
No 167 31.4 53 31.7% 1.00 1.00 0.82
Yes 365 68.6 126 34.5% 1.05 (0.70 to 1.58) 1.05 (0.70 to 1.58)
Age started selling sex†
10–14 26 4.8 10 38.5% 1.13 (0.48 to 2.66) 1.10 (0.46 to 2.59) 0.80
15–17 250 46.6 80 32.0% 1.00 1.00
18–19 150 27.9 53 35.3% 1.00 (0.63 to 1.58) 0.97 (0.61 to 1.54)
20–24 111 20.7 37 33.3% 0.81 (0.46 to 1.44) 0.77 (0.43 to 1.38)
Duration of selling sex†
,2 136 25.3 33 24.3% 0.53 (0.33 to 0.85) 0.51 (0.32 to 0.83) 0.02
2–3 236 44.0 89 37.7% 1.00 1.00
4+ 165 30.7 58 35.2% 0.83 (0.53 to 1.31) 0.86 (0.54 to 1.35)
No. of clients in the past mo‡
1–3 219 40.7 58 26.5% 1.00 1.00 0.09
4–9 173 32.2 58 33.5% 1.39 (0.90 to 2.17) 1.24 (0.78 to 1.96)
10+ 146 27.1 65 44.5% 2.17 (1.37 to 3.42) 1.71 (1.06 to 2.76)
Knowledge of HIV, perceived HIV risk support for PrEP
use, and access to Sisters services at enrollment
Knowledge of HIV prevention†
No 278 51.7 97 34.9% 1.00 1.00 0.72
Yes 260 48.3 87 32.3% 0.90 (0.63 to 1.30) 0.94 (0.65 to 1.35)
Perceived risk of HIV in the next 12 months
(excluding women self-reporting a positive HIV
test result at the last test, 37 missing data)§
No chance: no possibility of becoming infected 94 19.8 35 37.2% 0.86 (0.50 to 1.47) 0.96 (0.54 to 1.71) 0.79
Small chance: could happen but not likely 178 37.5 64 36.0% 1.00 1.00
Moderate chance: some possibility of becoming
infected
71 15.0 22 31.0% 0.80 (0.44 to 1.45) 0.83 (0.44 to 1.55)
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Seroconversion after 24 months was similar by whether
women reported ever using PrEP in and by 2019.13 Although
we did not collect adherence data and our measures of ever
and current PrEP use were self-reported, some women likely
seroconverted because of inadequate adherence and/or PrEP
discontinuation. A systematic review of 41 studies, represent-
ing 22,034 individuals, found high PrEP discontinuation at 1
month.29 Among the women in our study, low continued use
of PrEP was likely driven by a combination of supply-side
reasons and structural factors, including stigma related to HIV
and sex work, association of medication with ART, and lack
of social support.
Similar to our findings, qualitative data in the SEARCH
trial identified that, in addition to pill burden, PrEP use was
discontinued because of HIV-related/ART-related stigma,
relationship dissolution, and lack of support for use.23 A
Zimbabwean study among FSWs living with HIV found that
women experienced more stigma related to their sex work
than HIV stigma;30 a systematic review of 15 studies from
sub-Saharan Africa identified stigma related to sex work and
HIV as a barrier to HIV testing.31 Addressing stigma
associated with sex work, as well as HIV, may support
women’s PrEP use and adherence. Family support emerged
during qualitative interviews and quantitative findings suggest
lower PrEP use among women with less support from friends/
peers, with levels of PrEP use by perceived family support
similar to those reported by perceived support from friends/
peers. These findings align with evidence from a scoping
review of ART uptake and adherence among FSWs, which
found that social support facilitated uptake and adherence.32
TABLE 4. (Continued ) Enrollment Characteristics and Behaviors of Young Women Testing HIV-Negative and Followed up in 2019











Adjusted OR (95% CI)
Adjusted OR
(95% CI) P¶
High chance: likely to become infected 96 20.2 34 35.4% 1.02 (0.60 to 1.72) 1.06 (0.60 to 1.87)
I do not know 36 7.6 11 30.6% 0.66 (0.30 to 1.44) 0.63 (0.27 to 1.44)
I would receive support for PrEP use from:
friends/peers (N = 500)k
Agree/strongly agree 401 80.2 148 36.9% 1.00 1.00 0.03
Disagree/strongly disagree 99 19.8 24 24.2% 0.63 (0.38 to 1.05) 0.54 (0.31 to 0.95)
I would receive support for PrEP use from: sexual
partner (N = 487)k
Agree/strongly agree 271 55.7 88 32.5% 1.00 1.00 0.40
Disagree/strongly disagree 216 44.3 72 33.3% 1.28 (0.86 to 1.91) 1.21 (0.77 to 1.92)
I would receive support for PrEP use from: family
(N = 498)k
Agree/strongly agree 331 66.5 124 37.5% 1.00 1.00 0.30
Disagree/strongly disagree 167 33.5 45 27.0% 0.67 (0.44 to 1.02) 0.79 (0.50 to 1.23)
Had attended a Sisters clinic in the past 12 months†
No 404 75.1 108 26.7% 1.00 1.00 ,0.001
Yes 134 24.9 73 54.5% 3.37 (2.24 to 5.09) 2.92 (1.91 to 4.46)
Self-identification as a sex worker and offer of PrEP
between 2017–2019
How YWSS identified throughout the study§
Never identified as an FSW 105 19.8 28 26.7% 0.62 (0.37 to 1.05) 0.89 (0.51 to 1.57) 0.11
Did not identify as an FSW at enrollment, did at
follow-up
61 11.5 25 41.0% 1.13 (0.63 to 2.02) 1.46 (0.78 to 2.73)
Identified as an FSW at enrollment, not in follow-
up
109 20.6 27 24.8% 0.54 (0.33 to 0.90) 0.61 (0.36 to 1.04)
Identified as an FSW throughout the study 255 48.1 99 38.8% 1.00 1.00
Ever offered PrEP between 2017–2019
No 242 45.2 3 1.2% — — ,0.001
Yes 294 54.8 178 60.5%
FSWs–female sex workers; OR–odds ratio; All models adjusted for age and site.
*Additionally adjusted for marital status.
†Additionally adjusted for marital status and number of year selling sex.
‡Additionally adjusted for marital status, number of year selling sex, and attended a Sisters clinic in the past 12 months.
§Additionally adjusted for marital status, number of year selling sex, attended a Sisters clinic in the past 12 months, and number of clients in the previous mo.
kAdditionally adjusted for marital status, year selling sex, attended a Sisters clinic in the past 12 months, and perceived support for PrEP use from family/friends.
¶From the Wald test.
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Again, as PrEP becomes available in alternate and longer-
term formulations, these barriers may subside. However,
strategies to address HIV-related/ART-related stigma and
increase support for PrEP use remain critical.
CONCLUSION
To date, there are little data on PrEP use over time
among YWSS, including young FSWs aged ,25 years. As
PrEP is scaled-up across southern and eastern Africa,
understanding barriers to use among this group of women is
critical to support uptake and adherence.3,23 Our study shows
that barriers to PrEP initiation and continuation are similar to
those among other populations and in other countries. To
increase effectiveness among YWSS, proactive offers of PrEP
are needed combined with building social support among
peers, partners, and communities as knowledge and under-
standing of PrEP increases. Messaging to encourage PrEP use
should position PrEP in a way that matches women’s
perceptions regarding what places them at risk of HIV.
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